Results 151 to 160 of about 94,692 (282)

The imaginary divide between mental and “physical” health: Dismantling dualism and reductionism to address a monumental mistake in medicine

JCPP Advances, EarlyView.
Abstract Given the importance of the link between mental and other medical conditions, JCPP Advances organized a special issue on the topic; yet since then, very few papers have focused on this area. As such, this editorial perspective aims not only to highlight the link between mental and other medical conditions, but also to (1) explore the origins ...
Nicholas Fabiano, Marco Solmi, Kurt Kroenke, Brendon Stubbs, Joseph Firth, Fiona Gaughran, Katarzyna K. Machaczek, Christopher Palmer, Jess G. Fiedorowicz   +8 more
wiley   +1 more source

Understanding and improving the mental health of refugees and asylum‐seekers: Reflections from the closing panel of the 2024 International Society for Traumatic Stress Studies Annual Meeting

Journal of Traumatic Stress, EarlyView.
Abstract Forcible displacement due to war and persecution has reached unprecedented heights across the globe. The mental health impact of trauma and displacement on refugee communities is profound. Although there are several evidence‐based therapies that are efficacious in reducing symptoms of posttraumatic stress disorder and depression in refugees ...
Angela Nickerson, B. Heidi Ellis, Naser Morina, Frank Neuner, Lori Zoellner   +4 more
wiley   +1 more source

State of the Science: The epidemiology of posttraumatic stress disorder

Journal of Traumatic Stress, EarlyView.
Abstract Posttraumatic stress disorder (PTSD) is a mental health condition with widespread effects on mental and physical health and mortality. In this paper, we present the current state of research on the epidemiology of PTSD, including its prevalence, risk factors, and impact. The U.S.
Michelle Flesaker, Rachel Slimovitch, Brian Shiner, Jennifer A. Sumner, Jaimie L. Gradus   +4 more
wiley   +1 more source

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma, Panagiota Tsitsi, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'o, Aparna Wagle Shukla, Roongroj Bhidayasiri, Tiago A. Mestre, Alvaro Sanchez Ferro, Alberto J. Espay, Michelle H.S. Tosin, Matej Skorvanek, Ioanna Markaki   +14 more
wiley   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Spatial and functional profiles distinguish target sets of Parkinson’s disease and antipsychotic drugs with different clinical effects

Translational Psychiatry
Several studies have examined the genetic factors shared between Parkinson’s disease (PD) and schizophrenia (SZ), but the biological themes underlying their clinical relationships remain less explored.
Kalyani B. Karunakaran, Sanjeev Jain, Darius Widera, Graeme S. Cottrell   +3 more
doaj   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

High Prevalence and Clinical Impact of Fibromyalgia in Functional Motor Disorder

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fibromyalgia is characterized by widespread pain, fatigue, sleep and cognitive symptoms. It overlaps clinically with functional motor disorder (FMD), yet its prevalence and impact in FMD remain uncertain. Objective To determine the prevalence of fibromyalgia in FMD using the current criteria and evaluate its effects on motor ...
Tereza Serranová, Lucia Nováková, Martin Jirásek, Barbora Křupková, Evžen Růžička, Michele Tinazzi, Tomáš Sieger   +6 more
wiley   +1 more source

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

Movement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani, František Váša, Latha Velayudhan, Sagnik Bhattacharyya   +3 more
wiley   +1 more source